熱門資訊> 正文
内部人收购后，Cartesian反弹
2025-12-10 03:41
- Following a ~54% decline this year, Cartesian Therapeutics (RNAC) shares added nearly 20% on Tuesday after a board member of the cell therapy developer bought more than $200K worth of company stock.
- According to an SEC filing on Monday, Timothy Barabe, who joined Cartesian (RNAC) as a board member in 2016, purchased 30K shares of the company for an average price of about $6.86 last week. The $205.8K transaction took place on Thursday, increasing Barabe’s stake in RNAC to more than 54K shares.
- Cartesian went public following a reverse merger with then-publicly listed Selecta Biosciences in an all-stock deal announced in November 2023. On Saturday, the company posted initial data from an ongoing Phase 2 open-label trial for its lead asset, Descartes-08, in patients with systemic lupus erythematosus.
More on Cartesian Therapeutics
- Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis
- Cartesian expands development of CAR-T therapy Descartes-08 into myositis
- Seeking Alpha’s Quant Rating on Cartesian Therapeutics
- Historical earnings data for Cartesian Therapeutics
- Financial information for Cartesian Therapeutics
推薦文章
一周財經日曆 | 美聯儲新主席「呼之欲出」！特朗普下周或提前公佈；年末新股上市潮！卧安機器人、英矽智能等6只新股招股中
年終盤點 | 26年投資展望！美股有哪些經濟大事？
年終盤點 | 2025年港美股十大飆升ETF：年內暴漲620%！Palantir多頭槓桿ETF成年度黑馬
年終盤點 | 2025年港股牛股、妖股、熊股名單出爐！這家公司飆升超33倍后跌落神壇
華盛早報 | 科技股強勁反彈！納指一度漲超2%；哈塞特稱仍有很大的降息空間
年終盤點 | 美股七巨頭從「集體狂飆」到「殘酷分化」！誰能在2026年繼續坐莊？
打新攻略 | 2025港股IPO收官戰！6只招股+9只待上市+6只聆訊！打新資金如何巧妙「吃大肉」？
年末貨幣政策「壓軸大戲」：歐洲四央行同日登場，僅一家有望降息？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
